Breast cancer is the most common cancer in women in India. According to the National Cancer Registry Programme, breast cancer ...

A blood sample does not have an obvious odor to a person in a lab coat. But to an electronic nose, it can carry a chemical signature that points toward disease.

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 46th Annual Health ...

Researchers have developed an electronic nose that can “smell” early signs of ovarian cancer in the blood. The method is ...

Using machine learning, an electronic nose can "smell" early signs of ovarian cancer in the blood. The method is precise and, ...

Using machine learning, an electronic nose can "smell" early signs of ovarian cancer in the blood. The method is precise and, ...

Grail continues facing significant challenges as its stock plummeted over 45% after its landmark NHS-Galleri trial failed to ...

GRAIL reported that 2025 total revenue rose 17% year on year to $147.2 million, driven by a 26% increase in U.S. Galleri sales to $136.8 million, while net loss narrowed sharply to $408.4 million and ...

The Primary Endpoint of Statistically Significant Combined Stage III-IV Reduction Was Not Met, However A Favorable Trend Was Observed Over Time GRAIL Announces U.S. Sales Force Expansion Based on ...

BIOPREVENT’ AI tool predicts transplant-related immune conflict and mortality risk using biomarkers, helping doctors ...

MENLO PARK, Calif., Feb. 19, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial ...

Khaberni - Early cancer detection technologies are undergoing a radical transformation with the emergence of multicancer blood tests (MCED), which rely on the analysis of free DNA ...